Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday, November 2nd, MarketBeat Ratings reports. They presently have a $17.00 target price on the biotechnology company’s stock, down from their prior target price of $18.00. HC Wainwright’s price objective suggests a potential upside of 315.65% from the company’s previous close.
Several other research analysts also recently commented on the stock. Seaport Global Securities reissued a “buy” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a research note on Friday, October 6th. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. Finally, Stifel Nicolaus restated a “buy” rating and issued a $10.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.00.
Conatus Pharmaceuticals (CNAT) opened at $4.09 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.69 and a quick ratio of 2.69. Conatus Pharmaceuticals has a 1 year low of $1.73 and a 1 year high of $9.40.
Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.08). The firm had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 83.02%. During the same quarter last year, the business posted ($0.31) earnings per share. sell-side analysts expect that Conatus Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Conatus Pharmaceuticals’ (CNAT) Buy Rating Reiterated at HC Wainwright” was first published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/conatus-pharmaceuticals-cnat-buy-rating-reiterated-at-hc-wainwright/1750882.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC purchased a new stake in shares of Conatus Pharmaceuticals during the 2nd quarter valued at about $101,000. Wells Fargo & Company MN grew its stake in shares of Conatus Pharmaceuticals by 3,098.0% during the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 18,588 shares during the period. Bank of Montreal Can bought a new position in shares of Conatus Pharmaceuticals during the 2nd quarter valued at approximately $109,000. FNY Partners Fund LP grew its stake in shares of Conatus Pharmaceuticals by 98.0% during the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 9,800 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in shares of Conatus Pharmaceuticals during the 2nd quarter valued at approximately $115,000. 33.29% of the stock is owned by hedge funds and other institutional investors.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.